Seeking to Bring New Options to
Patients with Blood Cancers

Seeking to Bring New Options to Patients with Blood Cancers

ABOUT US

We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers.

PACRITINIB

CTI plans to evaluate pacritinib in the Phase 3 PACIFICA trial for patients with myelofibrosis and severe thrombocytopenia.

INVESTORS

For the latest corporate updates and press releases please visit the investor section of our website.

PATIENTS

We are actively recruiting individuals with myelofibrosis to participate in clinical trials.

Recent News

 

CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis

SEATTLE, July 18, 2019 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI” or “the Company”) today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration (“FDA” or “the Agency”) for the continued development of its investigational myelofibrosis treatment candidate, pacritinib… Read More

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20

SEATTLE, June 13, 2019 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City… Read More

CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5

SEATTLE, May 29, 2019 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City… Read More